A breakthrough weekly injectable treatment for Alzheimer's disease has received FDA approval in the United States, offering patients the potential to slow cognitive decline by up to eight years. This innovative self-administered therapy requires only 15 seconds for injection and can be given at home, eliminating frequent hospital visits. The medication represents a significant advancement in neurodegenerative disease management and may soon become accessible through the NHS, providing hope to millions affected by this progressive condition worldwide.

Summary auto-generated by AI from the original publisher's content. Editorial standards.